# Optos AI for DR with insights by verily

Rapid Capture. Rapid Analysis. Accurate Results.

> "Optos AI for DR has the potential to save sight and save healthcare practitioner's time whilst allowing clinicians to deliver the best clinical care."
>
> ~ Prof. Tunde Peto *Professor of Clinical Ophthalmology - Queen's University Belfast*

Optos AI for DR is the first CE-marked AI-based solution to automate the detection of more-than-mild diabetic retinopathy (DR) and diabetic macular odema, both vision-threatening diseases, using **opto**map ultra-widefield retinal images. The autonomous machine learning based system provides rapid automated evaluation of these vision-threatening diseases.

Optos ultra-widefield retinal imaging facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as pathologies attributable to diabetes. Combined with the Automated Retinal Disease Assessment AI tool developed by Verily and Google Health, healthcare practitioners can improve access to diabetic retinal screening whilst quickly and efficiently determining whether patients should be referred for further evaluation and management.

Optos AI for DR demonstrates excellent disease detection performance with sensitivity of over 96% and specificity of over 93%.[1]

Disease Confirmation
Presence and severity of DR is noted for each eye

Referral Recommendation
International classification on DR and DMO guidance for referral or follow-up

Reference Images
Reports include thumbnail copies of the evaluated images

1 Performance of a Diabetic Retinopathy Deep Learning Model for Ultra-widefield Imaging, Peto et al, Accepted for presentation at ARVO 2022

optos ®

Nikon

Optos plc
Tel: +44 (0)1383 843350
ics@optos.com

verily CE 0123